Fig. 4
Neural stem/progenitor cells at the ipsilesional neurogenic zones at 7 days after MCAO. a Representative immunohistochemistry of the ipsilesional neurogenic subventricular zone (SVZ, bregma = + 0.50 mm, the upper two rows) and the hippocampal subgranular zone (SGZ, bregma = − 1.22 mm, the lower two rows) in the normal WT (n = 6/each group), normal AHRcKO, WT-vehicle treated, WT-TMF treated, AHRflx/flx, and AHRcKO mice after MCAO. b Quantitative immunohistochemistry of SOX2-positive cell numbers in the SVZ. Note the increased SOX2-positive cells in the SVZ of normal AHRcKO mice (red arrows). WT-TMF-treated mice and AHRcKO mice showed significantly increased SOX2-positive cells in the ipsilesional SVZ after MCAO (red arrows). c, d Quantitative immunohistochemistry of DCX- and BrdU-double-positive proliferative neural progenitor cells (NPCs) in the SVZ (c) and the SGZ (d). After MCAO, DCX- and BrdU-positive NPCs increased in the SVZ but not in the SGZ. The TMF-treated WT mice and AHRcKO mice had significantly increased newly proliferative NPCs both in the SVZ and the SGZ of the hippocampus (red arrows). #p < 0.05 compared with the respective normal controls. +p < 0.05 AHRcKO-Normal compared with WT-Normal. *p < 0.05 AHRcKO compared with AHRflx/flx. The scale bars represent 10 μm